Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial.

被引：4

作者：

Cleary, James M.

Mayer, Robert J.

Van Cutsem, Eric

Yamashita, Fumiaki

Yoshisue, Kunihiro

Ieiri, Ichiro

Ohtsu, Atsushi

Lenz, Heinz-Josef

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Univ Hosp Leuven, Leuven, Belgium

[3] Taiho Pharmaceut Co Ltd, Tokyo, Japan

[4] Kyushu Univ, Fukuoka 812, Japan

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[6] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

来源：

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.2579

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2579

引用

页数：1